Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026GlobeNewsWire · 1 day ago
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026GlobeNewsWire · 2 days ago
New Strong Sell Stocks for October 14thZacks Investment Research · Oct 14, 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026GlobeNewsWire · Oct 5, 2026
Celcuity Appoints David Gryska To Its Board Of DirectorsGlobeNewsWire · Oct 2, 2026
Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?Defense World · Oct 2, 2026Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.16 | -$1.44 | Miss |
| May 14, 2026 | -$1.04 | -$0.97 | Beat |
| Mar 25, 2026 | -$1.06 | -$0.97 | Beat |
| Nov 12, 2025 | -$1.02 | -$0.92 | Beat |
| Aug 14, 2025 | -$0.90 | -$1.04 | Miss |
| May 14, 2025 | -$0.95 | -$0.86 | Beat |